Get the Stockscreener App
186.88
2.25%
4.11
After Hours:
187.98
1.10
+0.59%
Insmed Inc stock is traded at $186.88, with a volume of 1.63M.
It is up +2.25% in the last 24 hours and up +18.91% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$182.77
Open:
$182.92
24h Volume:
1.63M
Relative Volume:
0.67
Market Cap:
$39.50B
Revenue:
$447.02M
Net Income/Loss:
$-1.18B
P/E Ratio:
-30.23
EPS:
-6.1812
Net Cash Flow:
$-906.14M
1W Performance:
+11.94%
1M Performance:
+18.91%
6M Performance:
+157.48%
1Y Performance:
+169.67%
1-Day Range:
$182.09
$189.31
1-Week Range:
$167.00
$197.08
52-Week Range:
$60.40
$197.08
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
186.88 | 38.98B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.00 | 107.10B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
644.19 | 66.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.56 | 55.95B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
832.35 | 51.19B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Is Insmed Incorporated (IM8N) stock a buy before new product rolloutTrade Risk Assessment & Low Volatility Stock Recommendations - newser.com
Insmed (NASDAQ: INSM) to present at Jefferies Nov 18 and Evercore Dec 2; live webcasts - Stock Titan
Insmed, Inc. $INSM Shares Sold by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Historical volatility pattern of Insmed Incorporated visualizedGap Down & Entry and Exit Point Strategies - newser.com
Building trade automation scripts for Insmed IncorporatedPortfolio Risk Report & Safe Entry Zone Tips - newser.com
Bryce Point Capital LLC Invests $583,000 in Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Shares Bought by Atria Investments Inc - MarketBeat
What machine learning models say about Insmed IncorporatedMarket Risk Report & Pattern Based Trade Signal System - newser.com
Trend analysis for Insmed Incorporated this weekJuly 2025 Outlook & AI Enhanced Trading Signals - newser.com
How Insmed Incorporated (IM8N) stock compares with tech leadersJuly 2025 Summary & Trade Opportunity Analysis Reports - newser.com
3,909 Shares in Insmed, Inc. $INSM Purchased by Corton Capital Inc. - MarketBeat
Why Insmed Incorporated is moving todayWeekly Stock Recap & Weekly Breakout Watchlists - newser.com
What dividend safety score for Insmed Incorporated stockTake Profit & Risk Adjusted Swing Trade Ideas - newser.com
Will Insmed Incorporated stock benefit from automationTrend Reversal & Stepwise Swing Trade Plans - newser.com
Can Insmed Incorporated stock deliver surprise earnings beatPortfolio Risk Summary & Fast Moving Trade Plans - newser.com
Assetmark Inc. Acquires 5,892 Shares of Insmed, Inc. $INSM - MarketBeat
Nisa Investment Advisors LLC Sells 1,556 Shares of Insmed, Inc. $INSM - MarketBeat
What indicators show strength in Insmed Incorporated2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
Insmed Incorporated (INSM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Approval of Brinsupri Lifted Insmed Incorporated (INSM) in Q3 - Yahoo Finance
Insmed discovers new cathepsin C inhibitors - BioWorld MedTech
How Insmed Incorporated stock reacts to Fed rate cutsGap Down & Daily Profit Maximizing Tips - newser.com
Insmed Incorporated stock volume spike explainedJuly 2025 Volume & Fast Gain Swing Trade Alerts - newser.com
Earnings Beat: Insmed Incorporated (NASDAQ:INSM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Insmed, Inc. $INSM Position Reduced by Moody Aldrich Partners LLC - MarketBeat
Envestnet Asset Management Inc. Acquires 40,520 Shares of Insmed, Inc. $INSM - MarketBeat
Teacher Retirement System of Texas Has $4.93 Million Stake in Insmed, Inc. $INSM - MarketBeat
Insmed Incorporated (NASDAQ:INSM) Q3 2025 Earnings Call Transcript - Insider Monkey
Wells Fargo Maintains Insmed (INSM) Overweight Recommendation - Nasdaq
Insmed Inc (INSM) Stock Price, Trades & News - GuruFocus
Insmed (NASDAQ:INSM) Posts Earnings Results, Misses Estimates By $0.40 EPS - MarketBeat
Wells Fargo Raises Price Target for INSM to $217, Maintains Over - GuruFocus
Goldman Sachs Maintains Insmed (INSM) Buy Recommendation - Nasdaq
Insmed (NASDAQ:INSM) Hits New 12-Month HighTime to Buy? - MarketBeat
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake - sharewise.com
Goldman Sachs Boosts Insmed (INSM) Price Target to $225 | INSM S - GuruFocus
INSM: UBS Maintains 'Buy', Raises Price Target to $223 | INSM St - GuruFocus
Insmed Shares Likely to Gain From Brinsupri Sales, Untapped Pipeline, UBS Says - MarketScreener
Insmed stock surges as UBS raises price target on Brinsupri launch success - Investing.com Canada
Insmed (INSM) Sees Price Target Raised by RBC Capital to $215 | - GuruFocus
Insmed (INSM) Hits All-Time High as Firm Posts Highly Optimistic Outlook - Insider Monkey
Insmed Q3 2025 slides reveal strong BRINSUPRI debut, ARIKAYCE growth accelerates - Investing.com Australia
Insmed stock hits 52-week high at 170.3 USD By Investing.com - Investing.com Australia
RBC Raises Price Target on Insmed to $215 From $139, Keeps Outperform Rating - MarketScreener
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Sep 12 '25 |
Option Exercise |
23.75 |
56,520 |
1,342,350 |
112,981 |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Sep 12 '25 |
Sale |
145.45 |
76,520 |
11,129,927 |
36,461 |
| SHAROKY MELVIN MD | Director |
Sep 12 '25 |
Sale |
145.39 |
10,000 |
1,453,900 |
262,675 |
3.95%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):